<?xml version='1.0' encoding='utf-8'?>
<document id="24986093"><sentence text="Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro."><entity charOffset="25-33" id="DDI-PubMed.24986093.s1.e0" text="losartan" /><entity charOffset="38-49" id="DDI-PubMed.24986093.s1.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.24986093.s1.e0" e2="DDI-PubMed.24986093.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s1.e0" e2="DDI-PubMed.24986093.s1.e1" /></sentence><sentence text="Co-administration of anti-hypertension and anti-diabetic drugs is common in clinical settings" /><sentence text="" /><sentence text="In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16)"><entity charOffset="62-70" id="DDI-PubMed.24986093.s4.e0" text="losartan" /><entity charOffset="72-75" id="DDI-PubMed.24986093.s4.e1" text="LOS" /><entity charOffset="81-92" id="DDI-PubMed.24986093.s4.e2" text="glimepiride" /><entity charOffset="94-97" id="DDI-PubMed.24986093.s4.e3" text="GLP" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e0" e2="DDI-PubMed.24986093.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e0" e2="DDI-PubMed.24986093.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e0" e2="DDI-PubMed.24986093.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e0" e2="DDI-PubMed.24986093.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e1" e2="DDI-PubMed.24986093.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e1" e2="DDI-PubMed.24986093.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e1" e2="DDI-PubMed.24986093.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e2" e2="DDI-PubMed.24986093.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24986093.s4.e2" e2="DDI-PubMed.24986093.s4.e3" /></sentence><sentence text="" /><sentence text="Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0"><entity charOffset="14-22" id="DDI-PubMed.24986093.s6.e0" text="losartan" /><entity charOffset="102-113" id="DDI-PubMed.24986093.s6.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.24986093.s6.e0" e2="DDI-PubMed.24986093.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s6.e0" e2="DDI-PubMed.24986093.s6.e1" /></sentence><sentence text="669 ± 0" /><sentence text="055 µM, 0" /><sentence text="424 ± 0" /><sentence text="032 µM, 2" /><sentence text="557 ± 0" /><sentence text="058 µM, and 0" /><sentence text="667 ± 0" /><sentence text="039 µM, respectively" /><sentence text=" The inhibitory effect of glimepiride on losartan metabolism by CYP2C9*13 was marginal"><entity charOffset="26-37" id="DDI-PubMed.24986093.s15.e0" text="glimepiride" /><entity charOffset="41-49" id="DDI-PubMed.24986093.s15.e1" text="losartan" /><pair ddi="false" e1="DDI-PubMed.24986093.s15.e0" e2="DDI-PubMed.24986093.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s15.e0" e2="DDI-PubMed.24986093.s15.e1" /></sentence><sentence text=" The apparent Ki value of glimepiride with CYP2C9*3 (0"><entity charOffset="26-37" id="DDI-PubMed.24986093.s16.e0" text="glimepiride" /><entity charOffset="43-51" id="DDI-PubMed.24986093.s16.e1" text="CYP2C9*3" /><pair ddi="false" e1="DDI-PubMed.24986093.s16.e0" e2="DDI-PubMed.24986093.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s16.e0" e2="DDI-PubMed.24986093.s16.e1" /></sentence><sentence text="0416 ± 0" /><sentence text="0059 µM) was significantly lower than with CYP2C9*1 (0"><entity charOffset="43-51" id="DDI-PubMed.24986093.s18.e0" text="CYP2C9*1" /></sentence><sentence text="1476 ± 0" /><sentence text="0219 µM) and CYP2C9*16 (0" /><sentence text="2671 ± 0" /><sentence text="0456 µM)" /><sentence text=" On the other hand, losartan weakly inhibited the hydroxylation of glimepiride by P450 2C9 enzymes competitively"><entity charOffset="20-28" id="DDI-PubMed.24986093.s23.e0" text="losartan" /><entity charOffset="67-78" id="DDI-PubMed.24986093.s23.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.24986093.s23.e0" e2="DDI-PubMed.24986093.s23.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s23.e0" e2="DDI-PubMed.24986093.s23.e1" /></sentence><sentence text=" The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 &gt; CYP2C9*13 by 4 µM losartan"><entity charOffset="33-44" id="DDI-PubMed.24986093.s24.e0" text="glimepiride" /><entity charOffset="129-137" id="DDI-PubMed.24986093.s24.e1" text="losartan" /><pair ddi="false" e1="DDI-PubMed.24986093.s24.e0" e2="DDI-PubMed.24986093.s24.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s24.e0" e2="DDI-PubMed.24986093.s24.e1" /></sentence><sentence text=" No significant inhibition was observed when 0" /><sentence text="5 µM losartan was used"><entity charOffset="0-13" id="DDI-PubMed.24986093.s26.e0" text="5 µM losartan" /></sentence><sentence text="" /><sentence text="Given these results, the potential inhibition of losartan metabolism by CYP2C9*3, CYP2C9*13, and CYP2C9*16 in vivo by glimepiride deserves further investigation"><entity charOffset="49-57" id="DDI-PubMed.24986093.s28.e0" text="losartan" /><entity charOffset="118-129" id="DDI-PubMed.24986093.s28.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.24986093.s28.e0" e2="DDI-PubMed.24986093.s28.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s28.e0" e2="DDI-PubMed.24986093.s28.e1" /></sentence><sentence text=" These results may provide valuable information for optimizing the anti-hypertension efficacy of losartan when glimepiride is co-administered to patients"><entity charOffset="97-105" id="DDI-PubMed.24986093.s29.e0" text="losartan" /><entity charOffset="111-122" id="DDI-PubMed.24986093.s29.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.24986093.s29.e0" e2="DDI-PubMed.24986093.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24986093.s29.e0" e2="DDI-PubMed.24986093.s29.e1" /></sentence><sentence text="" /></document>